OBJECTIVE: To compare the socio-economic characteristics, clinical features and health-related quality of life in Hispanic SLE patients residing in Mexico and in the Southwest USA (Mexican and Texan, herein). METHODS: Mexican and Texan SLE patients (fulfilling ACR criteria) participating in separate longitudinal outcome studies were evaluated. Texan patients were randomly chosen to match total disease duration with the Mexican patients. Cross-sectional data for the Mexican patients were obtained by a US-trained investigator who had previously participated in data collection for the cohort to which the Texan patients belonged. Socio-economic and -demographic characteristics, clinical characteristics, disease activity (with SLAM-Revised), damage accrual (with SLICC/ACR Damage Index) and self-reported function (with Short Form-36) were compared between the two groups. RESULTS: Seventy Mexican patients were matched with either one or two Texan patients (n = 94) for a total of 164 patients. Mexican patients were younger. In age-adjusted analyses, the Mexican patients were more educated, had better health-related quality of life and overall less systemic SLE manifestations. Mexican patients were exposed more frequently to AZA. CONCLUSIONS: Texan patients had more severe disease than the Mexican patients. In multivariable analyses, Texan Hispanic ethnicity was significantly associated with high disease activity, but significance was not reached for damage. The discrepant findings observed between these two Hispanic groups of SLE patients may reflect socio-economic or biological factors. Given the global phenomenon of immigration, rheumatologists should be aware of the overall course and outcome of immigrant SLE patients if undesirable outcomes are to be prevented.
OBJECTIVE: To compare the socio-economic characteristics, clinical features and health-related quality of life in Hispanic SLEpatients residing in Mexico and in the Southwest USA (Mexican and Texan, herein). METHODS: Mexican and Texan SLEpatients (fulfilling ACR criteria) participating in separate longitudinal outcome studies were evaluated. Texan patients were randomly chosen to match total disease duration with the Mexican patients. Cross-sectional data for the Mexican patients were obtained by a US-trained investigator who had previously participated in data collection for the cohort to which the Texan patients belonged. Socio-economic and -demographic characteristics, clinical characteristics, disease activity (with SLAM-Revised), damage accrual (with SLICC/ACR Damage Index) and self-reported function (with Short Form-36) were compared between the two groups. RESULTS: Seventy Mexican patients were matched with either one or two Texan patients (n = 94) for a total of 164 patients. Mexican patients were younger. In age-adjusted analyses, the Mexican patients were more educated, had better health-related quality of life and overall less systemic SLE manifestations. Mexican patients were exposed more frequently to AZA. CONCLUSIONS: Texan patients had more severe disease than the Mexican patients. In multivariable analyses, Texan Hispanic ethnicity was significantly associated with high disease activity, but significance was not reached for damage. The discrepant findings observed between these two Hispanic groups of SLEpatients may reflect socio-economic or biological factors. Given the global phenomenon of immigration, rheumatologists should be aware of the overall course and outcome of immigrant SLEpatients if undesirable outcomes are to be prevented.
Authors: Juan Fernando Gallegos-Orozco; Ana Paula Fuentes; Juan Gerardo Argueta; Christian Pérez-Pruna; Carlos Hinojosa-Becerril; Ma Sara Sixtos-Alonso; Socorro Cruz-Castellanos; Gabriela Gutiérrez-Reyes; Marco Antonio Olivera-Martínez; Ma Concepción Gutiérrez-Ruiz; David Kershenobich Journal: Arch Med Res Date: 2003 Mar-Apr Impact factor: 2.235
Authors: Graciela S Alarcón; Gerald McGwin; Kemi Brooks; Jeffrey M Roseman; Barri J Fessler; Martha L Sanchez; Holly M Bastian; Alan W Friedman; Bruce A Baethge; John D Reveille Journal: Arthritis Rheum Date: 2002-08
Authors: R Graham Barr; Stephen Seliger; Gerald B Appel; Ricardo Zuniga; Vivette D'Agati; Jane Salmon; Jai Radhakrishnan Journal: Nephrol Dial Transplant Date: 2003-10 Impact factor: 5.992
Authors: J Calvo-Alén; J D Reveille; V Rodríguez-Valverde; G McGwin; B A Baethge; A W Friedman; G S Alarcón Journal: Lupus Date: 2003 Impact factor: 2.911
Authors: Bernardo A Pons-Estel; Luis J Catoggio; Mario H Cardiel; Enrique R Soriano; Silvana Gentiletti; Antonio R Villa; Isaac Abadi; Francisco Caeiro; Alejandro Alvarellos; Donato Alarcón-Segovia Journal: Medicine (Baltimore) Date: 2004-01 Impact factor: 1.889
Authors: L M Vilá; G S Alarcón; G McGwin; A W Friedman; B A Baethge; H M Bastian; B J Fessler; J D Reveille Journal: Rheumatology (Oxford) Date: 2003-11-17 Impact factor: 7.580
Authors: Elena Sánchez; Astrid Rasmussen; Laura Riba; Eduardo Acevedo-Vasquez; Jennifer A Kelly; Carl D Langefeld; Adrianne H Williams; Julie T Ziegler; Mary E Comeau; Miranda C Marion; Ignacio García-De La Torre; Marco A Maradiaga-Ceceña; Mario H Cardiel; Jorge A Esquivel-Valerio; Jacqueline Rodriguez-Amado; José Francisco Moctezuma; Pedro Miranda; Carlos E Perandones; Cecilia Castel; Hugo A Laborde; Paula Alba; Jorge L Musuruana; I Annelise Goecke; Juan-Manuel Anaya; Kenneth M Kaufman; Adam Adler; Stuart B Glenn; Elizabeth E Brown; Graciela S Alarcón; Robert P Kimberly; Jeffrey C Edberg; Luis M Vilá; Lindsey A Criswell; Gary S Gilkeson; Timothy B Niewold; Javier Martín; Timothy J Vyse; Susan A Boackle; Rosalind Ramsey-Goldman; R Hal Scofield; Michelle Petri; Joan T Merrill; John D Reveille; Betty P Tsao; Lorena Orozco; Vicente Baca; Kathy L Moser; Patrick M Gaffney; Judith A James; John B Harley; Teresa Tusié-Luna; Bernardo A Pons-Estel; Chaim O Jacob; Marta E Alarcón-Riquelme Journal: Arthritis Rheum Date: 2012-11
Authors: Vincent Biajoux; Alexandre Bignon; Christelle Freitas; Valérie Martinez; Marcus Thelen; Guadalupe Lima; Juan Jakez-Ocampo; Dominique Emilie; Luis Llorente; Karl Balabanian Journal: J Transl Med Date: 2012-12-18 Impact factor: 5.531